As part of our series focussing on medicines available in Australia, we have added a product review which outlines the pharmacology, efficacy, and adverse event profile of ivosidenib in adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation after at least one prior line of systemic therapy.
It also provides commentary and guidance from Associate Professor Matthew Burge, a medical oncologist and staff specialist at the Royal Brisbane Hospital and a visiting specialist at the Rockhampton Base Hospital.
Please login below to download this issue (PDF)